Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 18156031

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2007 Dec 22
First author
Escudier B

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2007 Dec 22;370(9605):2071-3. doi: 10.1016/S0140-6736(07)61874-1.
    note
    Source null
    related pmid
    18156012
    relationship
    Comment in
  2. citation
    Nat Clin Pract Oncol. 2008 Aug;5(8):436-7. doi: 10.1038/ncponc1162.
    note
    Source null
    related pmid
    18560387
    relationship
    Comment in
  3. citation
    Nat Clin Pract Urol. 2008 Aug;5(8):422-3. doi: 10.1038/ncpuro1157.
    note
    Source null
    related pmid
    18607403
    relationship
    Comment in
  4. citation
    Eur Urol. 2008 Oct;54(4):948-9. doi: 10.1016/j.eururo.2008.07.026.
    note
    Source null
    related pmid
    18953756
    relationship
    Comment in

Authors and identifiers

  1. name
    Escudier B
    type
    Author
  2. name
    Pluzanska A
    type
    Author
  3. name
    Koralewski P
    type
    Author
  4. name
    Ravaud A
    type
    Author
  5. name
    Bracarda S
    type
    Author
  6. name
    Szczylik C
    type
    Author
  7. name
    Chevreau C
    type
    Author
  8. name
    Filipek M
    type
    Author
  9. name
    Melichar B
    type
    Author
  10. name
    Bajetta E
    type
    Author
  11. name
    Gorbunova V
    type
    Author
  12. name
    Bay JO
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Escudier B
    type
    Author
  2. name
    Pluzanska A
    type
    Author
  3. name
    Koralewski P
    type
    Author
  4. name
    Ravaud A
    type
    Author
  5. name
    Bracarda S
    type
    Author
  6. name
    Szczylik C
    type
    Author
  7. name
    Chevreau C
    type
    Author
  8. name
    Filipek M
    type
    Author
  9. name
    Melichar B
    type
    Author
  10. name
    Bajetta E
    type
    Author
  11. name
    Gorbunova V
    type
    Author
  12. name
    Bay JO
    type
    Author
bibliography ids
  1. nci-bib-d908050a820628591b59ec28
book metadata
content sha256
d4d9e600e2e435d942665e7ccfa2c50b215f24972907cb34ff4cb6965b33dd92
document type
citation
dois
  1. 10.1016/S0140-6736(07)61904-7
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:18156031
immutable id
pubmed:18156031@d4d9e600e2e435d942665e7ccfa2c50b215f24972907cb34ff4cb6965b33dd92
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
9605
name
Lancet (London, England)
nlm unique id
2985213R
pages
2103-11
volume
370
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2007 Dec 22;370(9605):2071-3. doi: 10.1016/S0140-6736(07)61874-1.
    note
    Source null
    related pmid
    18156012
    relationship
    Comment in
  2. citation
    Nat Clin Pract Oncol. 2008 Aug;5(8):436-7. doi: 10.1038/ncponc1162.
    note
    Source null
    related pmid
    18560387
    relationship
    Comment in
  3. citation
    Nat Clin Pract Urol. 2008 Aug;5(8):422-3. doi: 10.1038/ncpuro1157.
    note
    Source null
    related pmid
    18607403
    relationship
    Comment in
  4. citation
    Eur Urol. 2008 Oct;54(4):948-9. doi: 10.1016/j.eururo.2008.07.026.
    note
    Source null
    related pmid
    18953756
    relationship
    Comment in
outcomes validated
false
pmid
18156031
provenance
batch id
89a0f2206e11ca092d02
provider
NCBI PubMed ESummary
record sha256
0dd9bf314fab0bc601eb45a5fb33b7c9c4a2d099adbc07793719adfcc8dd30c8
response sha256
7b1c355120884a7a596bcf7b4a243dc12308b7f7f0914c3fc71b0c8e8d79c708
retrieved at
2026-09-09T23:46:16.784581+00:00
publication date
display
2007 Dec 22
precision
day
year
2007
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, N.I.H., Extramural
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/18156031/
title
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.

Preserved source evidence · Not medical advice